EN 
ES 
FILSPARI (sparsentan)
FILSPARI (sparsentan) is a recently FDA approved treatment for IgA nephropathy (IgAN). There are also studies underway for the use of FILSPARI in other types of rare kidney disease (RKD), such as focal segmental glomerulosclerosis (FSGS).
How Does FILSPARI Work?
The goal of FILSPARI is to lower proteinuria. In the body, FILSPARI works to block two proteins: endothelin and angiotensin II. These two proteins are believed to contribute to kidney damage, such as seen in IgAN. For example, endothelin is thought to be involved in inflammation that can damage and scar kidney filters (glomeruli). Blocking these two proteins is protective for the kidneys and helps to reduce protein in urine.
What Does The Research Say About FILSPARI?
FILSPARI was and continues to be studied in clinical trials. FDA approval of FILSPARI for IgAN was based on the PROTECT clinical trial. In this trial, patients prescribed FILSPARI were compared to patients prescribed irbesartan. Irbesartan is medication that blocks angiotensin II only. FILSPARI blocks angiotensin II and endothelin.
FILSPARI was found to work better than ibersartan for lowering protein in urine. The patients in this study we all adults and had proteinuria levels of at least 1 gram per day.
After 36-weeks of treatment, patients prescribed FILSPARI had more improvement in proteinuria compared to patients taking irbesartan. On average, FILSPARI patients had 45% less protein in their urine compared to patients in the irbesartan group who had 15% less protein in their urine.
There are also trials to better understand FILSPARI for FSGS for proteinuria and eGFR.
*Note: The decision to prescribe a medication is the responsibility of your physician/primary care provider based on his/her evaluation of your condition. The above is meant for informational purposes only. Discuss this information and all information about drugs/medications with your physician before starting or stopping any medication.
Frequently Asked Questions
Based on report of the participants in the clinical studies, the side effects of FILSPARI may include:
• Low blood pressure
• Swelling in the arms or legs
• Dizziness
• High potassium in your blood
• Liver problems
There are some safety considerations for FILSPARI that you should discuss with your healthcare provider.
• FILSPARI is not recommended during pregnancy, as It can cause serious birth defects.
• There are some medications, such as angiotensin and endothelin receptor agonists, that are usually not prescribed with FILSPARI. Be sure to talk with your healthcare provider about what combination of medication is right for you.
*Note: The decision to prescribe a medication is the responsibility of your physician/medical team based on their evaluation of your condition. The above is meant for informational purposes only. Discuss this information and all information about drugs/medications with your physician before starting or stopping any medication.
FILSPARI is an oral treatment (taken by mouth). It is a non-immunosuppressive medication. That means it does not suppress your immune system. You may also see FILSPARI referred to as a “dual endothelin angiotensin II receptor antagonist” or DEARA. This title refers to how FILSPARI acts in the body: it blocks cells in the body from making endothelin and angiotensin II.
